CHICAGO – Improved technologies for molecular imaging agents and wider use of biomarkers may be moving the drug development industry away from the blockbuster model – and toward a niche market strategy where smaller patient populations are treated by more effective, targeted drugs – but that doesn't mean treating disease, particularly cancer, will get any less complex.